Source: International Congress 2015 – Cystic fibrosis: physiology, biomarkers, microbiology and miscellaneous
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Anne Neerincx (Nijmegen, Netherlands), Anne H. Neerincx, Brigitte Geurts, Jeroen J. Jansen, Marie-Fleur J. Habets, Johannes A. Booij, Jakko Van Ingen, Johan W. Mouton, Frans J.M. Harren, Leo A.J. Kluijtmans, Ron A. Wevers, Simona M. Cristescu, Peter J.F.M. Merkus. Volatile organic compounds emitted by pseudomonas aeruginosa and aspergillus fumigatus mono-cultures and in co-culture. Eur Respir J 2015; 46: Suppl. 59, 2057

Member's Comments

No comment yet.

Related content which might interest you: Coinfection with Pseudomonas aeruginosa and Aspergillus fumigatus in cystic fibrosis Source: Eur Respir Rev, 29 (158) 200011; 10.1183/16000617.0011-2020 Year: 2020 Pseudomonas aeruginosa from CF airways uses various strategies to outcompete staphylococcus aureus Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016 Role of stenotrophomonas maltophilia infection in CF pulmonary exacerbations Source: Annual Congress 2013 –Difficult and rare respiratory infections Year: 2013 Azithromycin therapy and pseudomonas aeruginosa isolation in a non-cystic fibrosis bronchiectasis cohort Source: International Congress 2015 – Adult bronchiectasis: risk factors and future perspectives Year: 2015 Bacterial cyanogenesis occurs in the cystic fibrosis lung Source: Eur Respir J 2008; 32: 329-333 Year: 2008 Genotypic studies of pseudomonas aeruginosa isolates from adult non-cystic fibrosis bronchiectasis patients Source: International Congress 2015 – Advances from translational research in respiratory infections Year: 2015 Cyanide in bronchoalveolar lavage is not diagnostic for Pseudomonas aeruginosa in children with cystic fibrosis Source: Eur Respir J 2011; 37: 553-558 Year: 2011 Training dogs to differentiate Pseudomonas aeruginosa from other cystic fibrosis bacterial pathogens: not to be sniffed at? Source: Eur Respir J, 54 (5) 1900970; 10.1183/13993003.00970-2019 Year: 2019 In vivo evidence for aspergillus fumigatus and pseudomonas aeruginosa driven th-17 type inflammatory responses in the lungs of CF-patients Source: Annual Congress 2009 - Cystic fibrosis: understanding a complex disease Year: 2009 Efficacy of ciprofloxacin against resistant mucoid or non-mucoid P. aeruginosa isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Should pseudomonas aeruginosa be the main target in bronchiectasis? Source: International Congress 2016 – Monitoring comorbidities Year: 2016 Patients with no cystic fibrosis bronchiectasis colonized by pseudomonas aeruginosa: Role of inhaled colistin Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections Year: 2014 Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa Source: Eur Respir J 2003; 22: 503-506 Year: 2003 Aminoglycoside use for pseudomonas aeruginosa in bronchiectasis Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Detection of Pseudomonas aeruginosa infection in cystic fibrosis patients by eNose technology Source: International Congress 2018 – Latest developments in cystic fibrosis Year: 2018 Pulmonary infections with pseudomonas aeruginosa Source: Eur Respir J 2004; 24: Suppl. 48, 642s Year: 2004 Temperate bacteriophages of pseudomonas aeruginosa as markers of bacterial adaptation in CF and non-CF bronchiectasis Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects Year: 2014 IL-10 induced T-cell tolerance to Aspergillus fumigatus and Pseudomonas aeruginosa in cystic fibrosis Source: Eur Respir J 2001; 18: Suppl. 33, 8s Year: 2001 Epidemiology and natural history of Pseudomonas aeruginosa airway infections in non-cystic fibrosis bronchiectasis Source: ERJ Open Res, 4 (2) 00162-2017; 10.1183/23120541.00162-2017 Year: 2018 Results of Tobramycin inhalation therapy in patients with noncystic fibrosis bronchiectasis with Pseudomonas Aeruginosa colonization: Real Life Management Source: Virtual Congress 2020 – New investigations of bronchiectasis and non-tuberculous mycobacteria Year: 2020